Update on the treatment of neuroendocrine tumors

Emilio Bajetta, Giuseppe Procopio, Leonardo Ferrari, Laura Catena, Michele Del Vecchio, Emilio Bombardieri

Research output: Contribution to journalArticlepeer-review


Neuroendocrine tumors represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. The basic study of the biological features of neuroendocrine tumors should allow the oncologist to identify those tumor subsets more sensitive to a particular medical treatment. For example, in metastatic or advanced disease, locoregional treatments, as well as radionuclide therapies, should be suggested only in selected cases. Although it has no significant effect on tumor growth, biotherapy with somatostatin analogs and/or interferon-α is recommended for either well-differentiated or functioning tumors. On the other hand, chemotherapy is effective in the treatment of those tumors characterized by a poor differentiation grade and a high proliferation rate. Novel therapies, new pharmacological formulations and more selective somatostatin analogs are now under clinical investigation for the treatment of neuroendocrine tumors.

Original languageEnglish
Pages (from-to)631-642
Number of pages12
JournalExpert Review of Anticancer Therapy
Issue number5
Publication statusPublished - Oct 2003


  • Anthracyclines
  • Dacarbazine
  • Etoposide
  • Fluoropyrimidines
  • Interferon-α
  • Lanreotide
  • Neuroendocrine tumors
  • Octreotide
  • Platinum analogs
  • Somatostatin analogs

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Update on the treatment of neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this